Trimel Pharmaceuticals Corporation
TSX : TRL

Trimel Pharmaceuticals Corporation

June 11, 2012 11:48 ET

Trimel to Present at Upcoming Investor Conference

TORONTO, ONTARIO--(Marketwire - June 11, 2012) - Trimel Pharmaceuticals Corporation (TSX:TRL) ("Trimel" or "the Company") today announced today that executive management will participate in the Bloom Burton & Co. Healthcare Investor Conference to be held June 21, 2012 at the Toronto Board of Trade. Mr. Tom Rossi, President and Chief Operating Officer, and Mr Kenneth Howling, Chief Financial Officer, are scheduled to present an overview of the Company and its product pipeline at 2:00 pm EDT. The presentation materials will also be available on the Trimel website at www.trimelpharmaceuticals.com.

For further information regarding Trimel Pharmaceuticals Corporation, please contact either Bruce Brydon, Chairman of the Board and Chief Executive Officer at (416) 679-0711 or Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at ir@trimelpharmaceuticals.com.

About Trimel

Trimel Pharmaceuticals Corporation (TSX:TRL) - Developing medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT™, a bio-adhesive intranasal Testosterone gel currently in Phase III clinical testing in the United States. CompleoTRT™ is under investigation for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit www.trimelpharmaceuticals.com.

Contact Information